When Antibiotics Leave a Lasting Mark: Understanding Fluoroquinolone-Associated Disability After Ciprofloxacin
A small but significant subset of patients report debilitating symptoms that persist long after completing a course of ciprofloxacin — a phenomenon now recognized by the FDA under the term fluoroquinolone-associated disability. This article examines what the clinical evidence says, how the FDA's position has evolved, and what patients experiencing prolonged symptoms should do next.